A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)

Clinical Trial OPEN
Loibl, Sibylle;
(2016)
  • Publisher: nct

To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes. Stimulating the immune cells of TNBC might therefore be an option for these patients to increase... View more
Share - Bookmark

  • Download from
    OpenTrials via OpenTrials (Clinical Trial, 2016)
  • Cite this research data